mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Key Points:

• Moderna and Merck announced that their personalized mRNA-based cancer vaccine, combined with Merck’s Keytruda, showed effectiveness in a Phase 3 trial for melanoma patients, extending recurrence-free survival (RFS) and distant metastasis-free survival (DMFS).
• The trial involved 1,137 patients with surgically removed stage IIB–IV melanoma, randomized to receive either the combination therapy or Keytruda alone in a double-blind, placebo-controlled study.
• The mRNA vaccine intismeran targets up to 34 unique mutations in a patient’s cancer cells, using a platform similar to Moderna’s COVID-19 vaccine to stimulate the immune system to attack cancer cells.
• Early data indicate statistically significant and clinically meaningful benefits, with prior Phase 2 results showing a 49% reduction in risk of recurrence or death and a 59% reduction in distant metastasis or death.
• Experts view this as a landmark advancement for personalized cancer treatment and mRNA therapies, though further detailed data on survival outcomes, patient subgroups, and quality of life are awaited to fully assess the treatment’s impact.